Treatment–resistant panic disorder: a systematic review

@article{Freire2016TreatmentresistantPD,
  title={Treatment–resistant panic disorder: a systematic review},
  author={Rafael Christophe Freire and Moren{\'a} Zugliani and Rafael F. Garcia and Ant{\^o}nio Eg{\'i}dio Nardi},
  journal={Expert Opinion on Pharmacotherapy},
  year={2016},
  volume={17},
  pages={159 - 168}
}
ABSTRACT Introduction: The prevalence of panic disorder (PD) in the population is high and these patients have work impairment, high unemployment rates, seek medical treatment more frequently and have more hospitalizations than people without panic symptoms. Despite the availability of pharmacological, psychological and combined treatments, approximately one-third of all PD patients have persistent panic attacks and other PD symptoms after treatment. Areas covered: MEDLINE/Pubmed, CENTRAL… 
View on Taylor & Francis
ncbi.nlm.nih.gov
29 Citations
Highly Influential Citations
2
Background Citations
9

29 Citations

Citation Type

Citation Type

Management of Treatment-Resistant Panic Disorder
TLDR
The personal perspective on the definition of “treatment resistance” as it relates to PD is discussed and personalized intervention strategies to increase favorable clinical outcomes are provided based on clinical expertise and review of experimental studies on the pathophysiology of PD.
Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018
TLDR
The efficacy of tranylcypromine, paroxetine, clonazepam, alprazolam and escitalopram is confirmed, and vortioxetine and TMS, with duration of 4 or more weeks, also seems to be effective.
Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines
TLDR
An updated systematic review of all of the studies that examined the efficacy and tolerability of SGAs in the treatment of PD, with or without other comorbid psychiatric disorders found a general lack of efficacy ofSGAs on panic symptoms.
Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years
TLDR
Given the lack of novel treatments, expanding a personalized approach to the existing medications seems to be the most feasible strategy to improve pharmacotherapy outcomes regarding PD.
From the Onset of Panic Symptoms to Getting to a Psychiatric Treatment : The Change by Improved Public Awareness of Panic Disorder in Korea
TLDR
The general process from the symptom onset to the psychiatric treatment in Korean panic patients and the effect of improved public awareness on it is investigated.
The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders
TLDR
Contrary to SAD and PD, this review found evidence for the use of second-generation antipsychotics in GAD and OCD, and first-generation anti-anxiety drugs cannot be recommended in anxiety disorders and OCD.
Personalized medicine in panic disorder: where are we now? A meta-regression analysis
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
TLDR
Some support for the use of vortioxetine in the management of panic disorder is provided, with a statistically significant decrease in the occurrence of panic attacks and a moderate improvement in the quality of life.
Panic disorder in general medical practice- A narrative review
The under-or misdiagnosis, and symptomatic treatment of the panic disorder (PD), despite high prevalent medical illness, is common among non-psychiatric physicians. The non-psychiatrist physician's…
Empirical evidence of the effect of personality pathology on the outcome of panic disorder.
...
...

References

SHOWING 1-10 OF 44 REFERENCES
New treatment options for panic disorder: clinical trials from 2000 to 2010
TLDR
A systematic review of the literature regarding the pharmacological treatment of Panic disorder in the last 10 years found that SSRIs and SNRIs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications.
Treating Medication-Resistant Panic Disorder: Predictors and Outcome of Cognitive-Behavior Therapy in a Brazilian Public Hospital
TLDR
CBT was effective for a sample of treatment-resistant patients with panic disorder with agoraphobia and depression as well as neurotic defense style was associated with a poorer outcome.
The 2-year prognosis of panic episodes in the general population
TLDR
The results suggest that the course of panic is diverse in the general population, thereby underlining the need for accurate predictors and given the large proportion with a relapse, relapse prevention should be part of any treatment programme.
Potential effectiveness and safety of olanzapine in refractory panic disorder
TLDR
Refractory panic disorder patients required a wide dose range averaging 12.3 mg/day of olanzapine to significantly improve or ablate panic attacks, and there were also statistically and clinically significant improvements in impairment over the course of the trial.
Cognitive behavior therapy for treatment-refractory panic disorder.
TLDR
It is observed that patients with panic disorder who are incompletely responsive or resistant to pharmacotherapeutic management may benefit from the addition of cognitive behavior therapy.
Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.
TLDR
Preliminary results demonstrate that pindolol has an augmenting effect on fluoxetine in patients with treatment-resistant panic disorder (PD).
Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison.
TLDR
SERTraline and paroxetine had equivalent efficacy in panic disorder, but sertraline was significantly better tolerated and was associated with significantly less clinical worsening during taper than paroxettine.
One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: Outcome and predictors of remission.
Venlafaxine extended release (XR) in the treatment of panic disorder
TLDR
Venlafaxine extended release (XR) was effective and well tolerated in both the short-term and long-term treatment of panic disorder and significantly improved patient quality of life and functioning.
Clinical and subthreshold panic disorder
TLDR
Psychiatric comorbidities and health‐care utilization are common among patients with subthreshold panic, and the relationship between varying degrees of panic symptomology and other mental health problems and indices of functioning impairment warrants further investigation.
...
...